Celyad Oncology H1 FY26 net loss narrows to €1.2 million; operating loss narrows to €1.2 million

• Celyad Oncology posted a net loss of €1.2 million for the first half, narrowing from €3.7 million a year earlier.
• Operating loss narrowed to €1.2 million from €3.7 million, while employee benefit expense fell 71.43% to €0.4 million.
• Other operating expenses dropped 64% to €1 million, and net cash used in operations decreased 54.55% to €1.5 million.
• Cash and cash equivalents stood at €0.1 million at June 30, and a €0.5 million capital increase on July 16 strengthened liquidity.
• The group expects existing cash and cash equivalents to fund operating and capital expenditures into 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celyad Oncology SA published the original content used to generate this news brief on September 23, 2026, and is solely responsible for the information contained therein.